A Randomized, Active-Controlled, Multicenter, Open label, Two Arm Study to Assess Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics with Pegfilgrastim PFS of Intas Pharmaceutical Limited Compared with Neupogen® Injection in Paediatric Patients Under 6 years of Age with Rhabdomyosarcoma or Wilms' Tumour on Myelosuppressive Chemotherapy (CmT) Regimen
Latest Information Update: 16 Sep 2021
At a glance
- Drugs Pegfilgrastim (Primary) ; Filgrastim
- Indications Rhabdomyosarcoma; Wilms' tumour
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
- 16 Sep 2021 New trial record